The use of auto-antibody testing in the evaluation of interstitial lung disease (ILD) – A practical approach for the pulmonologist

Respiratory Medicine

Volumn 113, Issue , 2016, Pages 80-92

  Bahmer, Thomas ^a   Romagnoli, Micaela ^b   Girelli, Francesco ^c   Claussen, Martin ^a   Rabe, Klaus F ^a  

^a GERMAN CENTER FOR LUNG RESEARCH   (Germany)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c MORGAGNI PIERANTONI HOSPITAL   (Italy)

Author keywords

ANA fluorescence pattern; CTD ILD; Diagnostic algorithm; IPAF; IPF; Serological testing

Indexed keywords

AMINO ACID TRANSFER RNA LIGASE; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CENTROMERE PROTEIN B ANTIBODY; CLINICALLY AMYOPATHIC DM POLYPEPTIDE ANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DOUBLE STRANDED DNA ANTIBODY; LA ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; NUCLESOME REMODELING DEACETYLASE COMPLEX ANTIBODY; POLYMYOSITIS SCLERODERMA OVERLAP SYNDROME RELATED ANTIBODY; RHEUMATOID FACTOR ANTIBODY; RNA POLYMERASE III ANTIBODY; RO ANTIBODY; SCL 70 ANTIBODY; SM ANTIBODY; TH TO ANTIBODY; U1 RIBONUCLEOPROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ALGORITHM; ANCA ASSOCIATED VASCULITIS; ANTISYNTHETASE SYNDROME; CONNECTIVE TISSUE DISEASE; HISTOPATHOLOGY; HUMAN; IMMUNOASSAY; INTERSTITIAL LUNG DISEASE; MIXED CONNECTIVE TISSUE DISEASE; MYOSITIS; NONHUMAN; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; PULMONOLOGIST; REVIEW; RHEUMATOID ARTHRITIS; SEROLOGY; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; CHEMISTRY; EARLY DIAGNOSIS; IMMUNOLOGY; LUNG DISEASES, INTERSTITIAL; SENSITIVITY AND SPECIFICITY;

ALGORITHMS; AUTOANTIBODIES; EARLY DIAGNOSIS; HUMANS; LUNG DISEASES, INTERSTITIAL; PULMONOLOGISTS; SENSITIVITY AND SPECIFICITY;

EID: 84964412556     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2016.01.019     Document Type: Review

References (152)

1. Ryu, J.H., Olson, E.J., Midthun, D.E., Swensen, S.J., Diagnostic approach to the patient with diffuse lung disease. Mayo Clin. Proc., 77, 2002, 1221.
2. Collard, H.R., King, T.E. Jr., Demystifying idiopathic interstitial pneumonia. Arch. Intern Med., 163, 2003, 17.
3. King, T.E. Jr., Clinical advances in the diagnosis and therapy of the interstitial lung diseases. Am. J. Respir. Crit. Care Med., 172, 2005, 268.
4. Bryson, T., Sundaram, B., Khanna, D., Kazerooni, E.A., Connective tissue disease-associated interstitial pneumonia and idiopathic interstitial pneumonia: similarity and difference. Semin. Ultrasound CT MR 35:1 (2014 Feb), 29–38.
5. Travis, W.D., Costabel, U., Hansell, D.M., King, T.E. Jr., Lynch, D.A., Nicholson, A.G., Ryerson, C.J., Ryu, J.H., Selman, M., Wells, A.U., Behr, J., Bouros, D., Brown, K.K., Colby, T.V., Collard, H.R., Cordeiro, C.R., Cottin, V., Crestani, B., Drent, M., Dudden, R.F., Egan, J., Flaherty, K., Hogaboam, C., Inoue, Y., Johkoh, T., Kim, D.S., Kitaichi, M., Loyd, J., Martinez, F.J., Myers, J., Protzko, S., Raghu, G., Richeldi, L., Sverzellati, N., Swigris, J., Valeyre, D., ATS/ERS committee on idiopathic interstitial pneumonias. An official American thoracic society/European respiratory society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 188:6 (2013 Sep 15), 733–748.
6. Arulkumaran, N., Periselneris, N., Gaskin, G., Strickland, N., Ind, P.W., Pusey, C.D., Salama, A.D., Interstitial lung disease and ANCA-associated vasculitis: a retrospective observational cohort study. Rheumatol. Oxf. 50:11 (2011 Nov), 2035–2043.
7. Homma, Y., Ohtsuka, Y., Tanimura, K., Kusaka, H., Munakata, M., Kawakami, Y., Ogasawara, H., Can interstitial pneumonia as the sole presentation of collagen vascular diseases be differentiated from idiopathic interstitial pneumonia?. Respiration 62:5 (1995), 248–251.
8. Solomon, J.J., Fischer, A., Connective tissue disease-associated interstitial lung disease: a focused review. J. Intensive Care Med. 30:7 (2015 Oct), 392–400.
9. Kalluri, M., Sahn, S.A., Oddis, C.V., Gharib, S.L., Christopher-Stine, L., Danoff, S.K., Casciola-Rosen, L., Hong, G., Dellaripa, P.F., Highland, K.B., Clinical profile of anti-PL-12 autoantibody Cohort study and review of the literature. Chest 135:6 (2009 Jun), 1550–1556.
10. Tzelepis, G.E., Toya, S.P., Moutsopoulos, H.M., Occult connective tissue diseases mimicking idiopathic interstitial pneumonias. Eur. Respir. J. 31 (2008), 11–20.
11. Suda, T., Kono, M., Nakamura, Y., Enomoto, N., Kaida, Y., Fujisawa, T., Imokawa, S., Yasuda, K., Hashizume, H., Yokomura, K., Toyoshima, M., Koshimizu, N., Suganuma, H., Shirai, T., Hashimoto, D., Inui, N., Colby, T.V., Chida, K., Distinct prognosis of idiopathic nonspecific interstitial pneumonia (NSIP) fulfilling criteria for undifferentiated connective tissue disease (UCTD). Respir. Med. 104:10 (2010 Oct), 1527–1534.
12. Ryerson, C.J., Vittinghoff, E., Ley, B., Lee, J.S., Mooney, J.J., Jones, K.D., Elicker, B.M., Wolters, P.J., Koth, L.L., King, T.E. Jr., Collard, H.R., Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest 145:4 (2014 Apr), 723–728.
13. Park, J.H., Kim, D.S., Park, I.N., Jang, S.J., Kitaichi, M., Nicholson, A.G., Colby, T.V., Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am. J. Respir. Crit. Care Med. 175:7 (2007 Apr 1), 705–711.
14. Corte, T.J., Copley, S.J., Desai, S.R., Zappala, C.J., Hansell, D.M., Nicholson, A.G., Colby, T.V., Renzoni, E., Maher, T.M., Wells, A.U., Significance of connective tissue disease features in idiopathic interstitial pneumonia. Eur. Respir. J. 39:3 (2012 Mar), 661–668.
15. Kinder, B.W., Collard, H.R., Koth, L., Daikh, D.I., Wolters, P.J., Elicker, B., Jones, K.D., King, T.E. Jr., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?. Am. J. Respir. Crit. Care Med. 176:7 (2007 Oct 1), 691–697.
16. Fischer, A., West, S.G., Swigris, J.J., Brown, K.K., du Bois, R.M., Connective tissue disease-associated interstitial lung disease: a call for clarification. Chest 138:2 (2010 Aug), 251–256.
17. Vij, R., Noth, I., Strek, M.E., Autoimmune-featured interstitial lung disease: a distinct entity. Chest 140:5 (2011 Nov), 1292–1299.
18. Fischer, A., Antoniou, K.M., Brown, K.K., Cadranel, J., Corte, T.J., du Bois, R.M., Lee, J.S., Leslie, K.O., Lynch, D.A., Matteson, E.L., Mosca, M., Noth, I., Richeldi, L., Strek, M.E., Swigris, J.J., Wells, A.U., West, S.G., Collard, H.R., Cottin, V., “ERS/ATS task force on undifferentiated forms of CTD-ILD”. An official European respiratory society/American thoracic society research statement: interstitial pneumonia with autoimmune features. Eur. Respir. J. 46:4 (2015 Oct), 976–987.
19. Raghu, G., Collard, H.R., Egan, J.J., Martinez, F.J., Behr, J., Brown, K.K., Colby, T.V., Cordier, J.F., Flaherty, K.R., Lasky, J.A., Lynch, D.A., Ryu, J.H., Swigris, J.J., Wells, A.U., Ancochea, J., Bouros, D., Carvalho, C., Costabel, U., Ebina, M., Hansell, D.M., Johkoh, T., Kim, D.S., King, T.E. Jr., Kondoh, Y., Myers, J., Müller, N.L., Nicholson, A.G., Richeldi, L., Selman, M., Dudden, R.F., Griss, B.S., Protzko, S.L., Schünemann, H.J., ATS/ERS/JRS/ALAT committee on idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 183:6 (2011 Mar 15), 788–824.
20. Bonaguri, C., Melegari, A., Ballabio, A., Parmeggiani, M., Russo, A., Battistelli, L., Aloe, R., Trenti, T., Lippi, G., Italian multicentre study for application of a diagnostic algorithm in autoantibody testing for autoimmune rheumatic disease: conclusive results. Autoimmun. Rev. 11:1 (2011 Nov), 1–5.
21. Man, A., Shojania, K., Phoon, C., Pal, J., de Badyn, M.H., Pi, D., Lacaille, D., An evaluation of autoimmune antibody testing patterns in a Canadian health region and an evaluation of a laboratory algorithm aimed at reducing unnecessary testing. Clin. Rheumatol. 32:5 (2013 May), 601–608.
22. Solomon, J.J., Chartrand, S., Fischer, A., Current approach to connective tissue disease-associated interstitial lung disease. Curr. Opin. Pulm. Med. 20:5 (2014 Sep), 449–456.
23. Voigt, J., Krause, C., Rohwäder, E., Saschenbrecker, S., Hahn, M., Danckwardt, M., Feirer, C., Ens, K., Fechner, K., Barth, E., Martinetz, T., Stöcker, W., Automated indirect immunofluorescence evaluation of antinuclear autoantibodies on HEp-2 cells. Clin. Dev. Immunol., 2012, 2012, 651058.
24. González, D.A., León, A.C., Varela, A.R., García, M.G., Rahola Mde, S., Pérez Mdel, C., Hernández, A.G., Falcón, M.J., Díaz, B.B., Autoantibody detection with indirect immunofluorescence on HEp-2 cells: starting serum dilutions for systemic rheumatic diseases. Immunol. Lett. 140:1–2 (2011 Oct 30), 30–35.
25. Tan, E.M., Feltkamp, T.E., Smolen, J.S., Butcher, B., Dawkins, R., Fritzler, M.J., Gordon, T., Hardin, J.A., Kalden, J.R., Lahita, R.G., Maini, R.N., McDougal, J.S., Rothfield, N.F., Smeenk, R.J., Takasaki, Y., Wiik, A., Wilson, M.R., Koziol, J.A., Range of antinuclear antibodies in “healthy” individuals. Arthritis Rheum. 40:9 (1997 Sep), 1601–1611.
26. Solomon, D.H., Kavanaugh, A.J., Schur, P.H., American college of rheumatology Ad Hoc committee on immunologic testing guidelines. Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum. 47:4 (2002 Aug), 434–444.
27. Nossent, H., Rekvig, O.P., Antinuclear antibody screening in this new millennium: farewell to the microscope?. Scand. J. Rheumatol. 30:3 (2001), 123–126 discussion 127–8.
28. Tozzoli, R., et al. Italian society of laboratory medicine study group on the diagnosis of autoimmune diseases. Guidelines for the laboratory use of autoantibody tests in the diagnosis and monitoring of autoimmune rheumatic diseases. Am. J. Clin. Pathol. 117:2 (2002 Feb), 316–324.
29. Kang, B.H., Park, J.K., Roh, J.H., Song, J.W., Lee, C.K., Kim, M., Jang, S.J., Colby, T.V., Kim, D.S., Clinical significance of serum autoantibodies in idiopathic interstitial pneumonia. J. Korean Med. Sci. 28:5 (2013 May), 731–737.
30. Mittoo, S., Gelber, A.C., Christopher-Stine, L., Horton, M.R., Lechtzin, N., Danoff, S.K., Ascertainment of collagen vascular disease in patients presenting with interstitial lung disease. Respir. Med. 103:8 (2009 Aug), 1152–1158.
31. Kavanaugh, A., Tomar, R., Reveille, J., Solomon, D.H., Homburger, H.A., Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens American college of pathologists. Arch. Pathol. Lab. Med. 124:1 (2000 Jan), 71–81.
32. Hervier, B., Uzunhan, Y., Hachulla, E., Benveniste, O., Nunes, H., Delaval, P., Musset, L., Dubucquoi, S., Wallaert, B., Hamidou, M., Antisynthetase syndrome positive for anti-threonyl-tRNA synthetase (anti-PL7) antibodies. Eur. Respir. J. 37:3 (2011 Mar), 714–717.
33. Love, L.A., Leff, R.L., Fraser, D.D., Targoff, I.N., Dalakas, M., Plotz, P.H., Miller, F.W., A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Med. Baltim. 70:6 (1991 Nov), 360–374.
34. Brouwer, R., Hengstman, G.J., Vree Egberts, W., Ehrfeld, H., Bozic, B., Ghirardello, A., Grøndal, G., Hietarinta, M., Isenberg, D., Kalden, J.R., Lundberg, I., Moutsopoulos, H., Roux-Lombard, P., Vencovsky, J., Wikman, A., Seelig, H.P., van Engelen, B.G., van Venrooij, W.J., Autoantibody profiles in the sera of European patients with myositis. Ann. Rheum. Dis. 60:2 (2001 Feb), 116–123.
35. Selva-O'Callaghan, A., Labrador-Horrillo, M., Muñoz-Gall, X., Martínez-Gomez, X., Majó-Masferrer, J., Solans-Laque, R., et al. Polymyositis/dermatomyositis associated lung disease: analysis of a series of 81 patients. Lupus 14 (2005), 534–542.
36. Dalakas, M., Hohlfeld, R., Polymyositis and dermatomyositis. Lancet 362 (2003), 971–982.
37. Cruellas, M.G., Viana Vdos, S., Levy-Neto, M., Souza, F.H., Shinjo, S.K., Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis. Clin. (Sao Paulo) 68:7 (2013 Jul), 909–914.
38. Targoff, I.N., Humoral immunity in polymyositis/dermatomyositis. J. Invest Dermatol 100 (1993), 116S–123S.
39. Hochberg, M.C., Feldman, D., Stevens, M.B., Arnett, F.C., Reichlin, M., Antibody to Jo-1 in polymyositis/dermatomyositis: association with interstitial pulmonary disease. J. Rheumatol. 11:5 (1984 Oct), 663–665.
40. Douglas, W.W., Tazelaar, H.D., Hartman, T.E., Hartman, R.P., Decker, P.A., Schroeder, D.R., Ryu, J.H., Polymyositis-dermatomyositis-associated interstitial lung disease. Am. J. Respir. Crit. Care Med. 164:7 (2001 Oct 1), 1182–1185.
41. Marie, I., Hachulla, E., Chérin, P., Dominique, S., Hatron, P., Hellot, M., et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum. 47 (2002), 614–622.
42. Cruellas, M.G., Viana Vdos, S., Levy-Neto, M., Souza, F.H., Shinjo, S.K., Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis. Clin. (Sao Paulo) 68:7 (2013 Jul), 909–914.
43. Mahler, M., Miller, F.W., Fritzler, M.J., Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. Autoimmun. Rev. 13:4–5 (2014 Apr-May), 367–371.
44. Frazier, A.R., Miller, R.D., Interstitial pneumonitis in association with polymyositis and dermatomyositis. Chest 65:4 (1974 Apr), 403–407.
45. Ji, S.Y., Zeng, F.Q., Guo, Q., Tan, G.Z., Tang, H.F., Luo, Y.J., Tang, Z.Q., Han, Y.F., Predictive factors and unfavourable prognostic factors of interstitial lung disease in patients with polymyositis or dermatomyositis: a retrospective study. Chin. Med. J. Engl. 123:5 (2010 Mar 5), 517–522.
46. Hirakata, M., Nagai, S., Interstitial lung disease in polymyositis and dermatomyositis. Curr. Opin. Rheumatol. 12:6 (2000 Nov), 501–508.
47. Fathi, M., Vikgren, J., Boijsen, M., et al. Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum. 59:5 (2008), 677–685.
48. Grathwohl, K.W., Thompson, J.W., Riordan, K.K., Roth, B.J., Dillard, T.A., Digital clubbing associated with polymyositis and interstitial lung disease. Chest 108:6 (1995 Dec), 1751–1752.
49. Kang, E.H., Lee, E.B., Shin, K.C., Im, C.H., Chung, D.H., Han, S.K., Song, Y.W., Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Rheumatol. Oxf. 44:10 (2005 Oct), 1282–1286.
50. Fathi, M., Lundberg, I.E., Tornling, G., Pulmonary complications of polymyositis and dermatomyositis. Semin. Respir. Crit. Care Med. 28 (2007), 451–458.
51. Tillie-Leblond, I., Wislez, M., Valeyre, D., Crestani, B., Rabbat, A., Israel-Biet, D., Humbert, M., Couderc, L.J., Wallaert, B., Cadranel, J., Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset. Thorax 63:1 (2008 Jan), 53–59.
52. Friedman, A.W., Targoff, I.N., Arnett, F.C., Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. Semin. Arthritis Rheum. 26:1 (1996 Aug), 459–467.
53. Mahler, M., Miller, F.W., Fritzler, M.J., Idiopathic inflammatory myopathies and the anti-synthetase syndrome: A comprehensive review. Autoimmun. Rev. 13:4–5 (2014 Apr-May), 367–371.
54. Marguerie, C., Bunn, C.C., Beynon, H.L., Bernstein, R.M., Hughes, J.M., So, A.K., Walport, M.J., Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q. J. Med. 77:282 (1990 Oct), 1019–1038.
55. Fathi, M., Dastmalchi, M., Rasmussen, E., Lundberg, I.E., Tornling, G., Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann. Rheum. Dis. 63:3 (2004 Mar), 297–301.
56. Hervier, B., Devilliers, H., Stanciu, R., Meyer, A., Uzunhan, Y., Masseau, A., Dubucquoi, S., Hatron, P.Y., Musset, L., Wallaert, B., Nunes, H., Maisonobe, T., Olsson, N.O., Adoue, D., Arlet, P., Sibilia, J., Guiguet, M., Lauque, D., Amoura, Z., Hachulla, E., Hamidou, M., Benveniste, O., Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmun. Rev. 12:2 (2012 Dec), 210–217.
57. Kalluri, M., Sahn, S.A., Oddis, C.V., Gharib, S.L., Christopher-Stine, L., Danoff, S.K., Casciola-Rosen, L., Hong, G., Dellaripa, P.F., Highland, K.B., Clinical profile of anti-PL-12 autoantibody Cohort study and review of the literature. Chest 135:6 (2009 Jun), 1550–1556.
58. Marie, I., Josse, S., Decaux, O., Dominique, S., Diot, E., Landron, C., Roblot, P., Jouneau, S., Hatron, P.Y., Tiev, K.P., Vittecoq, O., Noel, D., Mouthon, L., Menard, J.F., Jouen, F., Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome. Autoimmun. Rev. 11:10 (2012 Aug), 739–745.
59. Yamasaki, Y., Yamada, H., Nozaki, T., Akaogi, J., Nichols, C., Lyons, R., Loy, A.C., Chan, E.K., Reeves, W.H., Satoh, M., Unusually high frequency of autoantibodies to PL-7 associated with milder muscle disease in Japanese patients with polymyositis/dermatomyositis. Arthritis Rheum. 54:6 (2006 Jun), 2004–2009.
60. Fischer, A., Swigris, J.J., du Bois, R.M., Lynch, D.A., Downey, G.P., Cosgrove, G.P., Frankel, S.K., Fernandez-Perez, E.R., Gillis, J.Z., Brown, K.K., Anti-synthetase syndrome in ANA and anti-Jo-1 negative patients presenting with idiopathic interstitial pneumonia. Respir. Med. 103:11 (2009 Nov), 1719–1724.
61. Sato, S., Hirakata, M., Kuwana, M., Nakamura, K., Suwa, A., Inada, S., Mimori, T., Ikeda, Y., Clinical characteristics of Japanese patients with anti-PL-7 (anti-threonyl-tRNA synthetase) autoantibodies. Clin. Exp. Rheumatol. 23:5 (2005 Sep-Oct), 609–615.
62. Labirua-Iturburu, A., Selva-O'Callaghan, A., Vincze, M., Dankó, K., Vencovsky, J., Fisher, B., Charles, P., Dastmalchi, M., Lundberg, I.E., Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature. Med. Baltim. 91:4 (2012 Jul), 206–211.
63. Solomon, J., Swigris, J.J., Brown, K.K., Myositis-related interstitial lung disease and antisynthetase syndrome. J. Bras. Pneumol. 37:1 (2011 Jan-Feb), 100–109.
64. Targoff, I.N., Myositis specific autoantibodies. Curr. Rheumatol. Rep. 8:3 (2006 Jun), 196–203.
65. Targoff, I.N., Reichlin, M., The association between Mi-2 antibodies and dermatomyositis. Arthritis Rheum. 28:7 (1985 Jul), 796–803.
66. Cruellas, M.G., Viana Vdos, S., Levy-Neto, M., Souza, F.H., Shinjo, S.K., Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis. Clin. (Sao Paulo) 68:7 (2013 Jul), 909–914.
67. Euwer, R.L., Sontheimer, R.D., Amyopathic dermatomyositis (dermatomyositis siné myositis) presentation of six new cases and review of the literature. J. Am. Acad. Dermatol 24:6 Pt 1 (1991 Jun), 959–966.
68. Sontheimer, R.D., Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness?. J. Am. Acad. Dermatol 46 (2002), 626–636.
69. Euwer, R.L., Sontheimer, R.D., Amyopathic dermatomyositis: a review. J. Invest Dermatol 100 (1993), 124S–127S.
70. Saketkoo, L.A., Ascherman, D.P., Cottin, V., Christopher-Stine, L., Danoff, S.K., Oddis, C.V., Interstitial lung disease in idiopathic inflammatory myopathy. Curr. Rheumatol. Rev. 6:2 (2010 May), 108–119.
71. Cottin, V., Thivolet-Béjui, F., Reynaud-Gaubert, M., Cadranel, J., Delaval, P., Ternamian, P.J., Cordier, J.F., Groupe d'Etudes et de Recherche sur les Maladies ”Orphelines“ Pulmonaires. Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis. Eur. Respir. J. 22:2 (2003 Aug), 245–250.
72. Cottin, V., Donsbeck, A.V., Revel, D., Loire, R., Cordier, J.F., Nonspecific interstitial pneumonia. Individualization of a clinicopathologic entity in a series of 12 patients. Am. J. Respir. Crit. Care Med. 158 (1998), 1286–1293.
73. Sato, S., Hirakata, M., Kuwana, M., et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 52 (2005), 1571–1576.
74. Ikeda, N., Takahashi, K., Yamaguchi, Y., Inasaka, M., Kuwana, M., Ikezawa, Z., Analysis of dermatomyositis-specific autoantibodies and clinical characteristics in Japanese patients. J. Dermatol. 38:10 (2011 Oct), 973–979.
75. Gono, T., Sato, S., Kawaguchi, Y., Kuwana, M., Hanaoka, M., et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatol. Oxf. 51:9 (2012 Sep), 1563–1570.
76. Sato, S., Kuwana, M., Fujita, T., Suzuki, Y., Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod. Rheumatol. 23:3 (2013 May), 496–502.
77. Hanke, K., Brückner, C.S., Dähnrich, C., Huscher, D., Komorowski, L., Meyer, W., Janssen, A., Backhaus, M., Becker, M., Kill, A., Egerer, K., Burmester, G.R., Hiepe, F., Schlumberger, W., Riemekasten, G., Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients. Arthritis Res. Ther., 11(1), 2009, R22.
78. Mahler, M., Raijmakers, R., Novel aspects of autoantibodies to the PM/Scl complex: clinical, genetic and diagnostic insights. Autoimmun. Rev. 6:7 (2007 Aug), 432–437.
79. Raijmakers, R., Egberts, W.V., van Venrooij, W.J., Pruijn, G.J., The association of the human PM/Scl-75 autoantigen with the exosome is dependent on a newly identified N terminus. J. Biol. Chem. 278:33 (2003 Aug 15), 30698–30704.
80. Ben-Chetrit, E., Gandy, B.J., Tan, E.M., Sullivan, K.F., Isolation and characterization of a cDNA clone encoding the 60-kD component of the human SS-A/Ro ribonucleoprotein autoantigen. J. Clin. Invest. 83:4 (1989 Apr), 1284–1292.
81. Chan, E.K., Hamel, J.C., Buyon, J.P., Tan, E.M., Molecular definition and sequence motifs of the 52-kD component of human SS-A/Ro autoantigen. J. Clin. Invest. 87:1 (1991 Jan), 68–76.
82. Itoh, Y., Reichlin, M., Autoantibodies to the Ro/SSA antigen are conformation dependent I: Anti-60 kD antibodies are mainly directed to the native protein; anti-52 kD antibodies are mainly directed to the denatured protein. Autoimmunity 14:1 (1992), 57–65.
83. Pollock, W., Toh, B.H., Routine immunofluorescence detection of Ro/SS-A autoantibody using HEp-2 cells transfected with human 60 kDa Ro/SS-A. J. Clin. Pathol. 52:9 (1999 Sep), 684–687.
84. Locht, H., Pelck, R., Manthorpe, R., Clinical manifestations correlated to the prevalence of autoantibodies in a large (n=321) cohort of patients with primary Sjögren's syndrome: a comparison of patients initially diagnosed according to the Copenhagen classification criteria with the American-European consensus criteria. Autoimmun. Rev. 4:5 (2005 Jun), 276–281.
85. Franceschini, F., Cavazzana, I., Anti-Ro/SSA and La/SSB antibodies. Autoimmunity 38:1 (2005 Feb), 55–63.
86. Enomoto, Y., Takemura, T., Hagiwara, E., Iwasawa, T., Fukuda, Y., Yanagawa, N., Sakai, F., Baba, T., Nagaoka, S., Ogura, T., Prognostic factors in interstitial lung disease associated with primary Sjögren's syndrome: a retrospective analysis of 33 pathologically-proven cases. PLoS One, 8(9), 2013, e73774.
87. Kokosi, M., Riemer, E.C., Highland, K.B., Pulmonary involvement in Sjögren syndrome. Clin. Chest Med. 31:3 (2010 Sep), 489–500.
88. La Corte, R., Lo Mo Naco, A., Locaputo, A., Dolzani, F., Trotta, F., In patients with antisynthetase syndrome the occurrence of anti-Ro/SSA antibodies causes a more severe interstitial lung disease. Autoimmunity 39:3 (2006 May), 249–253.
89. Váncsa, A., Csípo, I., Németh, J., Dévényi, K., Gergely, L., Dankó, K., Characteristics of interstitial lung disease in SS-A positive/Jo-1 positive inflammatory myopathy patients. Rheumatol. Int. 29:9 (2009 Jul), 989–994.
90. Fischer, A., Swigris, J.J., du Bois, R.M., Groshong, S.D., Cool, C.D., Sahin, H., Lynch, D.A., Gillis, J.Z., Cohen, M.D., Meehan, R.T., Brown, K.K., Minor salivary gland biopsy to detect primary Sjogren syndrome in patients with interstitial lung disease. Chest 136:4 (2009 Oct), 1072–1078.
91. van den Hoogen, F., Khanna, D., Fransen, J., Johnson, S.R., Baron, M., Tyndall, A., Matucci-Cerinic, M., Naden, R.P., Medsger, T.A. Jr., Carreira, P.E., Riemekasten, G., Clements, P.J., Denton, C.P., Distler, O., Allanore, Y., Furst, D.E., Gabrielli, A., Mayes, M.D., van Laar, J.M., Seibold, J.R., Czirjak, L., Steen, V.D., Inanc, M., Kowal-Bielecka, O., Müller-Ladner, U., Valentini, G., Veale, D.J., Vonk, M.C., Walker, U.A., Chung, L., Collier, D.H., Ellen Csuka, M., Fessler, B.J., Guiducci, S., Herrick, A., Hsu, V.M., Jimenez, S., Kahaleh, B., Merkel, P.A., Sierakowski, S., Silver, R.M., Simms, R.W., Varga, J., Pope, J.E., 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann. Rheum. Dis. 72:11 (2013 Nov), 1747–1755.
92. Reveille, J.D., Solomon, D.H., Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum. 49 (2003), 399–412.
93. Wells, A.U., Interstitial lung disease in systemic sclerosis. Presse Med. 43:10 Pt 2 (2014 Oct), e329–e343.
94. Koenig, M., Dieudé, M., Senécal, J.L., Predictive value of antinuclear autoantibodies: the lessons of the systemic sclerosis autoantibodies. Autoimmun. Rev. 7:8 (2008 Sep), 588–593.
95. Walker, U.A., Tyndall, A., Czirják, L., Denton, C., Farge-Bancel, D., Kowal-Bielecka, O., Müller-Ladner, U., Bocelli-Tyndall, C., Matucci-Cerinic, M., Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma trials and research group database. Ann. Rheum. Dis. 66:6 (2007 Jun), 754–763.
96. Fritzler, M.J., Kinsella, T.D., The CREST syndrome: a distinct serologic entity with anticentromere antibodies. Am. J. Med. 69:4 (1980 Oct), 520–526.
97. Mitri, G.M., Lucas, M., Fertig, N., Steen, V.D., Medsger, T.A. Jr., A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum. 48:1 (2003 Jan), 203–209.
98. Kane, G.C., Varga, J., Conant, E.F., Spirn, P.W., Jimenez, S., Fish, J.E., Lung involvement in systemic sclerosis (scleroderma): relation to classification based on extent of skin involvement or autoantibody status. Respir. Med. 90:4 (1996 Apr), 223–230.
99. Diot, E., Giraudeau, B., Diot, P., Degenne, D., Ritz, L., Guilmot, J.L., Lemarié, E., Is anti-topoisomerase I a serum marker of pulmonary involvement in systemic sclerosis?. Chest 116:3 (1999 Sep), 715–720.
100. Steen, V., Medsger, T.A. Jr., Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum. 48:2 (2003 Feb), 516–522.
101. Briggs, D.C., Vaughan, R.W., Welsh, K.I., Myers, A., duBois, R.M., Black, C.M., Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis. Lancet 338:8768 (1991 Sep 14), 661–662.
102. Kuwana, M., Okano, Y., Pandey, J.P., Silver, R.M., Fertig, N., Medsger, T.A. Jr., Enzyme-linked immunosorbent assay for detection of anti-RNA polymerase III antibody: analytical accuracy and clinical associations in systemic sclerosis. Arthritis Rheum. 52:8 (2005 Aug), 2425–2432.
103. Hu, P.Q., Fertig, N., Medsger, T.A. Jr., Wright, T.M., Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthritis Rheum. 48:5 (2003 May), 1363–1373.
104. Okano, Y., Steen, V.D., Medsger, T.A. Jr., Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann. Intern Med. 119:10 (1993 Nov 15), 1005–1013.
105. Meyer, O., De Chaisemartin, L., Nicaise-Roland, P., Cabane, J., Tubach, F., Dieude, P., Hayem, G., Palazzo, E., Chollet-Martin, S., Kahan, A., Allanore, Y., Anti-RNA polymerase III antibody prevalence and associated clinical manifestations in a large series of French patients with systemic sclerosis: a cross-sectional study. J. Rheumatol. 37:1 (2010 Jan), 125–130.
106. Fischer, A., Pfalzgraf, F.J., Feghali-Bostwick, C.A., et al. Anti- Th/To-Positivity in a cohort of patients with idiopathic pulmonary fibrosis. J. Rheumatol. 33 (2006), 1600–1605.
107. Chifflot, H., Fautrel, B., Sordet, C., Chatelus, E., Sibilia, J., Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin. Arthritis Rheum. 37:4 (2008 Feb), 223–235.
108. Launay, D., Remy-Jardin, M., Michon-Pasturel, U., Mastora, I., Hachulla, E., Lambert, M., Delannoy, V., Queyrel, V., Duhamel, A., Matran, R., De Groote, P., Hatron, P.Y., High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. J. Rheumatol. 33:9 (2006 Sep), 1789–1801.
109. Bouros, D., Wells, A.U., Nicholson, A.G., Colby, T.V., Polychronopoulos, V., Pantelidis, P., Haslam, P.L., Vassilakis, D.A., Black, C.M., du Bois, R.M., Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am. J. Respir. Crit. Care Med. 165:12 (2002 Jun 15), 1581–1586.
110. Lomeo, R.M., Cornella, R.J., Schabel, S.I., Silver, R.M., Progressive systemic sclerosis sine scleroderma presenting as pulmonary interstitial fibrosis. Am. J. Med. 87:5 (1989 Nov), 525–527.
111. Bauer, P.R., Schiavo, D.N., Osborn, T.G., Levin, D.L., St Sauver, J., Hanson, A.C., Schroeder, D.R., Ryu, J.H., Influence of interstitial lung disease on outcome in systemic sclerosis: a population-based historical cohort study. Chest 144:2 (2013 Aug), 571–577.
112. Tramposch, H.D., Smith, C.D., Senecal, J.L., Rothfield, N., A long-term longitudinal study of anticentromere antibodies. Arthritis Rheum. 27:2 (1984 Feb), 121–124.
113. Ippolito, A., Wallace, D.J., Gladman, D., Fortin, P.R., Urowitz, M., Werth, V., Costner, M., Gordon, C., Alarcón, G.S., Ramsey-Goldman, R., Maddison, P., Clarke, A., Bernatsky, S., Manzi, S., Bae, S.C., Merrill, J.T., Ginzler, E., Hanly, J.G., Nived, O., Sturfelt, G., Sanchez-Guerrero, J., Bruce, I., Aranow, C., Isenberg, D., Zoma, A., Magder, L.S., Buyon, J., Kalunian, K., Dooley, M.A., Steinsson, K., van Vollenhoven, R.F., Stoll, T., Weisman, M., Petri, M., Autoantibodies in systemic lupus erythematosus: comparison of historical and current assessment of seropositivity. Lupus 20:3 (2011 Mar), 250–255.
114. Kavanaugh, A., Tomar, R., Reveille, J., Solomon, D.H., Homburger, H.A., Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens American college of pathologists. Arch. Pathol. Lab. Med. 124:1 (2000 Jan), 71–81.
115. Barada, F.A. Jr., Andrews, B.S., Davis, J.S. 4th, Taylor, R.P., Antibodies to Sm in patients with systemic lupus erythematosus correlation of Sm antibody titers with disease activity and other laboratory parameters. Arthritis Rheum. 24:10 (1981 Oct), 1236–1244.
116. Frodlund, M., Dahlström, O., Kastbom, A., Skogh, T., Sjöwall, C., Associations between antinuclear antibody staining patterns and clinical features of systemic lupus erythematosus: analysis of a regional Swedish register. BMJ Open, 3(10), 2013 Oct 25, e003608.
117. Almogren, A., Anti-double stranded antibody Association with titers and fluorescence patterns of anti-nuclear antibody in systemic lupus erythematosus. Saudi Med. J. 31:1 (2010 Jan), 32–36.
118. Mohan, T.C., Nadarajah, M., Sng, E.H., Relation of antinuclear fluorescence patterns and titres to autoantibody prevalence. Ann. Acad. Med. Singap. 18:4 (1989 Jul), 339–344.
119. Verstegen, G., Duyck, M.C., Meeus, P., Ravelingien, I., De Vlam, K., Detection and identification of antinuclear antibodies (ANA) in a large community hospital. Acta Clin. Belg. 64:4 (2009 Jul-Aug), 317–323.
120. Brasington, R.D., Furst, D.E., Pulmonary disease in systemic lupus erythematosus. Clin. Exp. Rheumatol. 3:3 (1985 Jul-Sep), 269–276.
121. Pego-Reigosa, J.M., Medeiros, D.A., Isenberg, D.A., Respiratory manifestations of systemic lupus erythematosus: old and new concepts. Best. Pract. Res. Clin. Rheumatol. 23:4 (2009 Aug), 469–480.
122. Weinrib, L., Sharma, O.P., Quismorio, F.P. Jr., A long-term study of interstitial lung disease in systemic lupus erythematosus. Semin. Arthritis Rheum. 20:1 (1990 Aug), 48–56.
123. Sharp, G.C., Irvin, W.S., Tan, E.M., Gould, R.G., Holman, H.R., Mixed connective tissue disease–an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am. J. Med. 52:2 (1972 Feb), 148–159.
124. Cervera, R., Khamashta, M.A., Hughes, G.R., 'Overlap' syndromes. Ann. Rheum. Dis. 49:11 (1990 Nov), 947–948.
125. Bodolay, E., Szekanecz, Z., Dévényi, K., Galuska, L., Csípo, I., Vègh, J., Garai, I., Szegedi, G., Evaluation of interstitial lung disease in mixed connective tissue disease (MCTD). Rheumatol. Oxf. 44:5 (2005 May), 656–661.
126. Gunnarsson, R., Aaløkken, T.M., Molberg, Ø., Lund, M.B., Mynarek, G.K., Lexberg, A.S., Time, K., Dhainaut, A.S., Bertelsen, L.T., Palm, O., Irgens, K., Becker-Merok, A., Nordeide, J.L., Johnsen, V., Pedersen, S., Prøven, A., Garabet, L.S., Gran, J.T., Prevalence and severity of interstitial lung disease in mixed connective tissue disease: a nationwide, cross-sectional study. Ann. Rheum. Dis. 71:12 (2012 Dec), 1966–1972.
127. Lundberg, I.E., The prognosis of mixed connective tissue disease. Rheum. Dis. Clin. North Am. 31:3 (2005 Aug), 535–547 vii-viii.
128. Reimer, G., Huschka, U., Keller, J., Kammerer, R., Hornstein, O.P., Immunofluorescence studies in progressive systemic sclerosis (scleroderma) and mixed connective tissue disease. Br. J. Dermatol. 109:1 (1983 Jul), 27–36.
129. Hagen, E.C., Andrassy, K., Csernok, E., Daha, M.R., Gaskin, G., Gross, W.L., Hansen, B., Heigl, Z., Hermans, J., Jayne, D., Kallenberg, C.G., Lesavre, P., Lockwood, C.M., Lüdemann, J., Mascart-Lemone, F., Mirapeix, E., Pusey, C.D., Rasmussen, N., Sinico, R.A., Tzioufas, A., Wieslander, J., Wiik, A., Van der Woude, F.J., Development and standardization of solid phase assays for the detection of anti-neutrophil cytoplasmic antibodies (ANCA) A report on the second phase of an international cooperative study on the standardization of ANCA assays. J. Immunol. Methods 196:1 (1996 Sep 13), 1–15.
130. Hagen, E.C., Daha, M.R., Hermans, J., Andrassy, K., Csernok, E., Gaskin, G., Lesavre, P., Lüdemann, J., Rasmussen, N., Sinico, R.A., Wiik, A., van der Woude, F.J., Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis EC/BCR Project for ANCA Assay Standardization. Kidney Int. 53:3 (1998 Mar), 743–753.
131. Lionaki, S., Blyth, E.R., Hogan, S.L., Hu, Y., Senior, B.A., Jennette, C.E., Nachman, P.H., Jennette, J.C., Falk, R.J., Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum. 64:10 (2012 Oct), 3452–3462.
132. Tervaert, J.W., Goldschmeding, R., Elema, J.D., Limburg, P.C., van der Giessen, M., Huitema, M.G., Koolen, M.I., Hené, R.J., The, T.H., van der Hem, G.K., Association of autoantibodies to myeloperoxidase with different forms of vasculitis. Arthritis Rheum. 33:8 (1990 Aug), 1264–1272.
133. Eschun, G.M., Mink, S.N., Sharma, S., Pulmonary interstitial fibrosis as a presenting manifestation in perinuclear antineutrophilic cytoplasmic antibody microscopic polyangiitis. Chest 123:1 (2003 Jan), 297–301.
134. Nozu, T., Kondo, M., Suzuki, K., Tamaoki, J., Nagai, A., A comparison of the clinical features of ANCA-positive and ANCA-negative idiopathic pulmonary fibrosis patients. Respiration 77:4 (2009), 407–415.
135. Foulon, G., Delaval, P., Valeyre, D., Wallaert, B., Debray, M.P., Brauner, M., Nicaise, P., Cadranel, J., Cottin, V., Tazi, A., Aubier, M., Crestani, B., ANCA-associated lung fibrosis: analysis of 17 patients. Respir. Med. 102:10 (2008 Oct), 1392–1398.
136. Guillevin, L., Durand-Gasselin, B., Cevallos, R., Gayraud, M., Lhote, F., Callard, P., Amouroux, J., Casassus, P., Jarrousse, B., Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum. 42:3 (1999 Mar), 421–430.
137. Whiting, P.F., Smidt, N., Sterne, J.A., Harbord, R., Burton, A., Burke, M., Beynon, R., Ben-Shlomo, Y., Axford, J., Dieppe, P., Systematic review: accuracy of anti-citrullinated Peptide antibodies for diagnosing rheumatoid arthritis. Ann. Intern Med. 152:7 (2010 Apr 6), 456–464 W155-66.
138. Horton, M.R., Rheumatoid arthritis associated interstitial lung disease. Crit. Rev. Comput. Tomogr. 45:5–6 (2004), 429–440.
139. Olson, A.L., Swigris, J.J., Sprunger, D.B., Fischer, A., Fernandez-Perez, E.R., Solomon, J., Murphy, J., Cohen, M., Raghu, G., Brown, K.K., Rheumatoid arthritis-interstitial lung disease-associated mortality. Am. J. Respir. Crit. Care Med. 183:3 (2011 Feb 1), 372–378.
140. Bongartz, T., Nannini, C., Medina-Velasquez, Y.F., Achenbach, S.J., Crowson, C.S., Ryu, J.H., Vassallo, R., Gabriel, S.E., Matteson, E.L., Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum. 62:6 (2010 Jun), 1583–1591.
141. Raghu, G., Nyberg, F., Morgan, G., The epidemiology of interstitial lung disease and its association with lung cancer. Br. J. Cancer 91:Suppl 2 (2004 Aug), S3–S10.
142. Mapel, D.W., Hunt, W.C., Utton, R., Baumgartner, K.B., Samet, J.M., Coultas, D.B., Idiopathic pulmonary fibrosis: survival in population based and hospital based cohorts. Thorax 53:6 (1998 Jun), 469–476.
143. Valeyre, D., Freynet, O., Dion, G., Bouvry, D., Annesi-Maesano, I., Nunes, H., Epidemiology of interstitial lung diseases. Presse Med. 39:1 (2010 Jan), 53–59.
144. Kornum, J.B., Christensen, S., Grijota, M., Pedersen, L., Wogelius, P., Beiderbeck, A., Sørensen, H.T., The incidence of interstitial lung disease 1995-2005: a Danish nationwide population-based study. BMC Pulm. Med., 8, 2008 Nov 4, 24.
145. Demedts, M., Wells, A.U., Antó, J.M., Costabel, U., Hubbard, R., Cullinan, P., Slabbynck, H., Rizzato, G., Poletti, V., Verbeken, E.K., Thomeer, M.J., Kokkarinen, J., Dalphin, J.C., Taylor, A.N., Interstitial lung diseases: an epidemiological overview. Eur. Respir. J. Suppl. 32 (2001 Sep), 2s–16s.
146. Tansey, D., Wells, A.U., Colby, T.V., Ip, S., Nikolakoupolou, A., du Bois, R.M., Hansell, D.M., Nicholson, A.G., Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology 44:6 (2004 Jun), 585–596.
147. Romagnoli, M., Nannini, C., Piciucchi, S., Girelli, F., Gurioli, C., Casoni, G., Ravaglia, C., Tomassetti, S., Ch, Gurioli, Gavelli, G., Carloni, A., Dubini, A., Cantini, F., Chilosi, M., Poletti, V., Idiopathic nonspecific interstitial pneumonia: an interstitial lung disease associated with autoimmune disorders?. Eur. Respir. J. 38:2 (2011 Aug), 384–391.
148. Sato, T., Fujita, J., Yamadori, I., Ohtsuki, Y., Yoshinouchi, T., Bandoh, S., Tokuda, M., Ishida, T., Non-specific interstitial pneumonia; as the first clinical presentation of various collagen vascular disorders. Rheumatol. Int. 26:6 (2006 Apr), 551–555.
149. de Lauretis, A., Veeraraghavan, S., Renzoni, E., Review series: Aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ?. Chron. Respir. Dis. 8:1 (2011), 53–82.
150. Koduri, G., Norton, S., Young, A., Cox, N., Davies, P., Devlin, J., Dixey, J., Gough, A., Prouse, P., Winfield, J., Williams, P., ERAS (Early Rheumatoid Arthritis Study). Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. Rheumatol. Oxf. 49:8 (2010 Aug), 1483–1489.
151. Marie, I., Hatron, P.Y., Dominique, S., Cherin, P., Mouthon, L., Menard, J.F., Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum. 63:11 (2011 Nov), 3439–3447.
152. Park, I.N., Jegal, Y., Kim, D.S., Do, K.H., Yoo, B., Shim, T.S., Lim, C.M., Lee, S.D., Koh, Y., Kim, W.S., Kim, W.D., Jang, S.J., Kitaichi, M., Nicholson, A.G., Colby, T.V., Clinical course and lung function change of idiopathic nonspecific interstitial pneumonia. Eur. Respir. J. 33:1 (2009 Jan), 68–76.